vTv Therapeutics — Third Quarter 2026 Earnings Summary

Financial Performance:

• Reported net loss of $11.6 million ($0.94 per share) for the three months ended September 30, 2026, compared to $8.7 million ($1.08 per share) in the same period in 2025.
• Revenue was $0 for the three months ended September 30, 2026, compared to $0 in the prior year period.
• Research and development expenses increased to $7.5 million for the quarter ended September 30, 2026, from $7.0 million in the prior year period, driven by continued investment in the Phase 3 CATT1 trial.
• General and administrative expenses rose to $4.9 million for the quarter ended September 30, 2026, from $3.7 million in the prior year period, primarily due to higher share-based compensation and payroll-related expenses.
• Cash and cash equivalents decreased to $77.2 million as of September 30, 2026, from $88.9 million as of December 31, 2025.
• Interest income for the quarter ended September 30, 2026, was $0.7 million, compared to $0.4 million in the prior year period.
• Total liabilities decreased to $8.9 million as of September 30, 2026, from $25.5 million as of December 31, 2025, largely due to a reduction in contract liabilities from $18.7 million to $1.8 million.
• Total stockholders' equity increased to $69.7 million as of September 30, 2026, from $64.4 million as of December 31, 2025.

Guidance and Future Outlook:

• The Company expects to have sufficient cash to fund operations well through the anticipated topline data readout for the Phase 3 CATT1 trial in mid-2027.
• Topline results for the Phase 3 CATT1 trial are expected in mid-2027.

Business Segments and Product Lines:

• Completed enrollment in the Phase 3 CATT1 trial evaluating cadisegliatin for type 1 diabetes (T1D), randomizing 166 participants to receive cadisegliatin 800 mg once daily, 800 mg twice daily, or placebo over six months.
• Randomized the first participant in the Phase 2a Hybrid CATT1 pilot study evaluating cadisegliatin in individuals with T1D who use hybrid closed-loop (HCL) insulin delivery systems.
• Received FDA Orphan Drug Designation for HPPD, an oral, first-in-class Nrf2/Bach1 modulator being investigated as a potential treatment for sickle cell disease.
• Cadisegliatin is a liver-selective glucokinase activator with Breakthrough Therapy designation from the FDA.
• Preclinical studies for HPPD showed it increased fetal hemoglobin and reduced oxidative stress and red blood cell sickling in a sickle cell disease mouse model.

Market and Competitive Landscape:

• A quantitative survey of 674 adults with T1D (429 using automated insulin delivery systems) estimated that approximately 54% experience at least one dimension of hypoglycemia-related burden, indicating persistent unmet medical need despite advanced insulin delivery technology.
• The Company hosted a Key Opinion Leader (KOL) event in October 2026 to highlight cadisegliatin's potential to address hypoglycemia.

Risks and Challenges:

• The release notes that cadisegliatin and HPPD are under investigation, and their safety and efficacy have not been established.
• There is no guarantee that these products will receive health authority approval or become commercially available.
• Forward-looking statements involve risks and uncertainties, including clinical trial timing, cash sufficiency, and potential partnering outcomes, which could cause actual results to differ materially from expectations.

Management Commentary and Tone:

• Paul Sekhri, Chairman, President and CEO, described completing Phase 3 CATT1 enrollment as a significant milestone and expressed confidence in reporting topline results in mid-2027.
• Management emphasized that hypoglycemia remains a persistent burden for T1D patients even with advanced insulin delivery technology.
• The Company views the FDA Orphan Drug Designation for HPPD as strengthening its ability to advance partnering discussions and create shareholder value.

Other Key Points:

• The Company will present at the 9th Annual Evercore HealthCONx Conference on December 2, 2026, in Coral Gables, FL.
• The Phase 3 CATT1 primary efficacy endpoint will assess the incidence of level 2 and level 3 hypoglycemic events.
• Secondary endpoints for the CATT1 trial include changes in hemoglobin A1c, time in target glucose range, and the incidence of diabetic ketoacidosis.
• The Company reported a net loss of $0.5 million ($0.04 per share) for the nine months ended September 30, 2026, compared to a net loss of $19.8 million ($2.80 per share) for the same period in 2025.
• Revenue for the nine months ended September 30, 2026, was $36.8 million, compared to $0 in the prior year period.